Hey there! Welcome!
Get updated on
stem cell
stem cell
stem cell
Top Picks

calendar
14 Jul, 26
dot
link
ESHRE 2026
Key highlights of the sessions on fertility preservation presented at ESHRE from 5th to 8th July 2026 in London, UK.

calendar
14 Jul, 26
dot
link
ESHRE 2026
Key highlights of the sessions on global and socio-cultural aspects of infertility presented at ESHRE from 5th to 8th July 2026 in London, UK.

calendar
23 Jul, 26
dot
link
J. Crit. Care.
  • Fluid creep and maintenance fluids are major contributors to ICU fluid burden.
  • Higher exposure was independently associated with major adverse kidney events within 30 days (MAKE30).
  • Increased risk extended to mortality, renal replacement therapy, and persistent renal dysfunction.
  • Reducing fluid creep may represent a modifiable target for ICU fluid stewardship.

calendar
23 Jul, 26
dot
link
Diabetes Res Clin Pr...
  • A meta-analysis of 22 RCTs (n=29,023) in adults with T2DM or overweight/obesity showed that tirzepatide significantly reduced major adverse cardiovascular events (MACE; OR:0.87) & all-cause mortality (OR:0.84)
  • The MACE odds lowered by 2.8% per 1 mg dose increase of tirzepatide, indicating a dose-response effect
  • No significant benefit was seen for individual MACE components or HF hospitalization.

calendar
23 Jul, 26
dot
link
Diabetes Obes Metab.
  • In a prospective cohort (n=7633), early-pregnancy metabolically healthy & unhealthy overweight/obesity (MHO/MUO) were linked to higher fetal estimated weight (EFW) & abdominal circumference (AC) Z-scores at 28–36 wks & raised risk of EFW/AC overgrowth
  • MUO also raised the risk of head circumference (HC) undergrowth (OR 1.22)
  • MH normal weight (MUNW) was linked to lower HC Z-scores, partly mediated by GDM (11.2–16%)

calendar
22 Jul, 26
dot
link
J. Cosmet. Dermatol.
  • In a randomized trial of 466 subjects, L-carnosine composite injections every 4 weeks (3 sessions) significantly improved skin quality versus control.
  • Week 12 responder rates were higher for GAIS (86.5% vs 5.3%), SDDIS (82.9% vs 5.7%), AFLS (36.1% vs 4.6%), and ASRS (47.5% vs 5.0%) (all p<0.05).
  • Treatment was well tolerated; 41.2% experienced mainly mild, transient injection-site reactions.

calendar
25 Jun, 26